Comparing pneumococcal conjugate vaccine schedules based on 3 and 2 primary doses: systematic review and meta-analysis

Scott, Pippa; Rutjes, Anne W S; Bermetz, Lilian; Robert, Nadège; Scott, Susana; Lourenço, Tania; Egger, Matthias; Low, Nicola (2011). Comparing pneumococcal conjugate vaccine schedules based on 3 and 2 primary doses: systematic review and meta-analysis. Vaccine, 29(52), pp. 9711-9721. Amsterdam: Elsevier 10.1016/j.vaccine.2011.07.042

[img] Text
Scott Vaccine 2011.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (638kB) | Request a copy

Background Pneumococcal conjugate vaccines (PCV) were first licensed for use with 3 primary doses in infancy and a booster dose. The evidence for the effects of different schedules was examined in this systematic review and meta-analysis. Methods We searched 12 databases and trial registers up to March 2010. We selected randomised controlled trials (RCTs), cohort and case–control studies making direct comparisons between PCV schedules with (2p) or (3p) primary doses, with (+1) or without (+0) a booster dose. We extracted data on clinical, nasopharyngeal carriage and immunological outcomes and used meta-analysis to combine results where appropriate. Results Seropositivity levels (antibody concentration ≥0.35 μg/ml) following 3p and 2p PCV schedules were high for most serotypes (5 RCTs). Differences between schedules were generally small and tended to favour 3p schedules, particularly for serotypes 6B and 23F; between-study heterogeneity was high. Seropositivity levels following 3p+1 and 2p+1 schedules were similar but small differences favouring 3p+1 schedules were seen for serotypes 6B and 23F. We did not identify any RCTs reporting clinical outcomes for these comparisons. In 2 RCTs there was weak evidence of a reduction in carriage of S. pneumoniae serotypes included in the vaccine when 3p+0 schedules were compared to 2p+0 at 6 months of age. Conclusions Most data about the relative effects of different PCV schedules relate to immunological outcomes. Both 3p and 2p schedules result in high levels of seropositivity. The clinical relevance of differences in immunological outcomes between schedules is not known. There is an absence of clinical outcome data from RCTs with direct comparisons of any 2p with any 3p PCV schedule.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Pre-clinic Human Medicine > Institute of Social and Preventive Medicine

UniBE Contributor:

Scott, Pippa; Rutjes, Anne; Bermetz, Lilian; Robert, Nadège; Egger, Matthias and Low, Nicola

ISSN:

0264-410X

Publisher:

Elsevier

Language:

English

Submitter:

Factscience Import

Date Deposited:

04 Oct 2013 14:21

Last Modified:

11 Nov 2015 10:51

Publisher DOI:

10.1016/j.vaccine.2011.07.042

PubMed ID:

21821080

Web of Science ID:

000298623000025

BORIS DOI:

10.7892/boris.7308

URI:

https://boris.unibe.ch/id/eprint/7308 (FactScience: 212506)

Actions (login required)

Edit item Edit item
Provide Feedback